Agenus (NASDAQ:AGEN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Agenus (NASDAQ:AGEN) from a hold rating to a buy rating in a report published on Saturday.

Several other analysts have also weighed in on the company. B. Riley Financial restated a “buy” rating and set a $14.00 price target (up from $8.00) on shares of Agenus in a report on Thursday. Zacks Research lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. HC Wainwright boosted their price objective on shares of Agenus from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $22.00.

Agenus Trading Up 4.3%

AGEN opened at $7.82 on Friday. The stock has a 50-day moving average of $4.14 and a 200 day moving average of $3.71. Agenus has a 12 month low of $2.71 and a 12 month high of $8.70. The firm has a market cap of $349.96 million, a P/E ratio of 4.92 and a beta of 1.55.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Monday, May 11th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). The company had revenue of $33.74 million for the quarter, compared to analysts’ expectations of $129.50 million. Agenus had a net margin of 50.49% and a negative return on equity of 31.66%. On average, research analysts forecast that Agenus will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD purchased a new stake in Agenus during the fourth quarter worth $77,000. LPL Financial LLC increased its holdings in shares of Agenus by 20.3% in the 4th quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 3,943 shares during the period. Sherbrooke Park Advisers LLC purchased a new position in shares of Agenus in the 3rd quarter valued at $64,000. Squarepoint Ops LLC bought a new position in shares of Agenus in the 3rd quarter worth $54,000. Finally, Jump Financial LLC bought a new stake in Agenus during the second quarter valued at about $55,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.